Mechanisms for an effect of acetylcysteine on renal function after exposure to radio-graphic contrast material: Study protocol

BMC Clinical Pharmacology

Volumn 12, Issue , 2012, Pages

  Sandilands, Euan A ^a,b   Cameron, Sharon ^c   Paterson, Frances ^c   Donaldson, Sam ^c   Briody, Lesley ^c   Crowe, Jane ^c   Donnelly, Julie ^c   Thompson, Adrian ^b   Johnston, Neil R ^b   Mackenzie, Ivor ^d   Uren, Neal ^a   Goddard, Jane ^a   Webb, David J ^b   Megson, Ian L ^d   Bateman, Nicholas ^a,b   Eddleston, Michael ^a,b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c Queen's Medical Research Institute   (United Kingdom)

^d UNIVERSITY OF THE HIGHLANDS AND ISLANDS   (United Kingdom)

Author keywords

Acetylcysteine; Contrast media; Contrast induced nephropathy; Kidney; Prevention

Indexed keywords

ACETYLCYSTEINE; CREATININE; CYSTATIN C; IODIXANOL; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; ACUTE PHASE PROTEIN; CONTRAST MEDIUM; HAVCR1 PROTEIN, HUMAN; LCN2 PROTEIN, HUMAN; LIPOCALIN; MEMBRANE PROTEIN; ONCOPROTEIN; VIRUS RECEPTOR;

4 AMINOHIPPURIC ACID CLEARANCE; ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CROSSOVER PROCEDURE; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; BLOOD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; KIDNEY; KIDNEY CIRCULATION; MIDDLE AGED; NATRIURESIS; PATHOPHYSIOLOGY; URINE;

ACETYLCYSTEINE; ACUTE-PHASE PROTEINS; CONTRAST MEDIA; CROSS-OVER STUDIES; CYSTATIN C; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY; LIPOCALINS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NATRIURESIS; PROTO-ONCOGENE PROTEINS; RECEPTORS, VIRUS; RENAL CIRCULATION; RENAL INSUFFICIENCY, CHRONIC;

EID: 84856499496     PISSN: None     EISSN: 14726904     Source Type: Journal    
DOI: 10.1186/1472-6904-12-3     Document Type: Article

References (51)

1. Parfrey P. The clinical epidemiology of contrast-induced nephropathy. Cardiovasc Intervent Radiol 2005, 28(Suppl 2):S3-11.
2. McCullough PA, Adam A, Becker CR, Davidson C, Lameire N, Stacul F, et al. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol 2006, 98:5K-13K.
3. Mehran R, Caixeta A. N-acetylcysteine in preventing contrast-induced nephropathy. To give, or not to give: that is the question. Rev Esp Cardiol 2010, 63:9-11.
4. Stacul F. Reducing the risks for contrast-induced nephropathy. Cardiovasc Intervent Radiol 2005, 28(Suppl 2):S12-S18.
5. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study. Arch Intern Med 1990, 150:1237-1242. 10.1001/archinte.1990.00390180067011, 2353856.
6. Gleeson TG, Bulugahapitiya S. Contrast-induced nephropathy. AJR Am J Roentgenol 2004, 183:1673-1689.
7. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002, 39:930-936. 10.1053/ajkd.2002.32766, 11979336.
8. Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol 2000, 36:1542-1548. 10.1016/S0735-1097(00)00917-7, 11079656.
9. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000, 11:177-182.
10. Baker CS, Wragg A, Kumar S, De Palma R, Baker LR, Knight CJ. A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. J Am Coll Cardiol 2003, 41:2114-2118. 10.1016/S0735-1097(03)00487-X, 12821233.
11. Stacul F, Adam A, Becker CR, Davidson C, Lameire N, McCullough PA, et al. Strategies to reduce the risk of contrast-induced nephropathy. Am J Cardiol 2006, 98:59K-77K. 10.1016/j.amjcard.2006.01.024, 16949381.
12. Acetylcysteine for Prevention of Renal Outcomes in Patients Undergoing Coronary and Peripheral Vascular Angiography: Main Results From the Randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT). Circulation 2011, 124:1250-1259.
13. Briguori C, Visconti G, Focaccio A, Airoldi F, Valgimigli M, Sangiorgi GM, et al. Renal Insufficiency After Contrast Media Administration Trial II (REMEDIAL II): RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury. Circulation 2011,
14. Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, et al. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA 2004, 291:2328-2334. 10.1001/jama.291.19.2328, 15150204.
15. Erdogan A, Davidson CJ. Recent clinical trials of iodixanol. Rev Cardiovasc Med 2003, 4(Suppl 5):S43-S50.
16. Sandler CM. Contrast-agent-induced acute renal dysfunction--is iodixanol the answer?. N Engl J Med 2003, 348:551-553. 10.1056/NEJMe020183, 12571263.
17. Solomon R. The role of osmolality in the incidence of contrast-induced nephropathy: a systematic review of angiographic contrast media in high risk patients. Kidney Int 2005, 68:2256-2263. 10.1111/j.1523-1755.2005.00684.x, 16221227.
18. Briguori C, Colombo A, Airoldi F, Morici N, Sangiorgi GM, Violante A, et al. Nephrotoxicity of low-osmolality versus iso-osmolality contrast agents: impact of N-acetylcysteine. Kidney Int 2005, 68:2250-2255. 10.1111/j.1523-1755.2005.00683.x, 16221226.
19. Aspelin P, Aubry P, Fransson SG, Strasser R, Willenbrock R, Berg KJ. Nephrotoxic effects in high-risk patients undergoing angiography. N Engl J Med 2003, 348:491-499. 10.1056/NEJMoa021833, 12571256.
20. Bartholomew BA, Harjai KJ, Dukkipati S, Boura JA, Yerkey MW, Glazier S, et al. Impact of nephropathy after percutaneous coronary intervention and a method for risk stratification. Am J Cardiol 2004, 93:1515-1519. 10.1016/j.amjcard.2004.03.008, 15194023.
21. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol 2004, 44:1393-1399.
22. Rudnick MR, Davidson C, Laskey W, Stafford JL, Sherwin PF. Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. Am Heart J 2008, 156:776-782. 10.1016/j.ahj.2008.05.023, 18946896.
23. Bagshaw SM, McAlister FA, Manns BJ, Ghali WA. Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. Arch Intern Med 2006, 166:161-166. 10.1001/archinte.166.2.161, 16432083.
24. Eddleston M, Goddard J, Bateman N. N-acetylcysteine for contrast nephropathy: more clinical science is required. Arch Intern Med 2006, 166:1668-1669.
25. Sunman W, Hughes AD, Sever PS. Anaphylactoid response to intravenous acetylcysteine. Lancet 1992, 339:1231-1232.
26. Manjunath G, Sarnak MJ, Levey AS. Estimating the glomerular filtration rate. Dos and don'ts for assessing kidney function. Postgrad Med 2001, 110:55-62.
27. Hoffmann U, Fischereder M, Kruger B, Drobnik W, Kramer BK. The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. J Am Soc Nephrol 2004, 15:407-410. 10.1097/01.ASN.0000106780.14856.55, 14747387.
28. Jakobsen JA. Renal effects of iodixanol in healthy volunteers and patients with severe renal failure. Acta Radiol Suppl 1995, 399:191-195.
29. Nelson L, Lewin N, Howland M, Hoffman R, Goldfrank L, Flomenbaum N. Goldfrank's Toxicologic Emergencies 2010, 9.
30. Shalansky SJ, Vu T, Pate GE, Levin A, Humphries KH, Webb JG. N-acetylcysteine for prevention of radiographic contrast material-induced nephropathy: is the intravenous route best?. Pharmacotherapy 2005, 25:1095-1103. 10.1592/phco.2005.25.8.1095, 16207100.
31. Prescott LF, Donovan JW, Jarvie DR, Proudfoot AT. The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. Eur J Clin Pharmacol 1989, 37:501-506. 10.1007/BF00558131, 2598989.
32. Sandilands EA, Bateman DN. Adverse reactions associated with acetylcysteine. Clin Toxicol (Phila) 2009, 47:81-88.
33. GE Healthcare Visipaque 320: summary of product characteristics. Accessed 13 Jan 06, GE Healthcare.
34. Sweetman SCE. Martindale: the extra pharmacopoeia 2005, 34.
35. Nyman U, Almen T, Aspelin P, Hellstrom M, Kristiansson M, Sterner G. Contrast-medium-Induced nephropathy correlated to the ratio between dose in gram iodine and estimated GFR in ml/min. Acta Radiol 2005, 46:830-842. 10.1080/02841850500335051, 16392608.
36. Schnurr E, Lahme W, Kuppers H. Measurement of renal clearance of inulin and PAH in the steady state without urine collection. Clin Nephrol 1980, 13:26-29.
37. Stevens LA, Levey AS. Measurement of kidney function. Med Clin North Am 2005, 89:457-473. 10.1016/j.mcna.2004.11.009, 15755462.
38. Rickli H, Benou K, Ammann P, Fehr T, Brunner-La Rocca HP, Petridis H, et al. Time course of serial cystatin C levels in comparison with serum creatinine after application of radiocontrast media. Clin Nephrol 2004, 61:98-102.
39. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008, 48:463-493. 10.1146/annurev.pharmtox.48.113006.094615, 2742480, 17937594.
40. Nielsen BS, Borregaard N, Bundgaard JR, Timshel S, Sehested M, Kjeldsen L. Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. Gut 1996, 38:414-420. 10.1136/gut.38.3.414, 1383072, 8675096.
41. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003, 14:2534-2543. 10.1097/01.ASN.0000088027.54400.C6, 14514731.
42. Wagener G, Jan M, Kim M, Mori K, Barasch JM, Sladen RN, et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006, 105:485-491. 10.1097/00000542-200609000-00011, 16931980.
43. Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S, et al. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011, 57:772-779. 10.1161/HYPERTENSIONAHA.110.167486, 21357275.
44. Fang LS, Sirota RA, Ebert TH, Lichtenstein NS. Low fractional excretion of sodium with contrast media-induced acute renal failure. Arch Intern Med 1980, 140:531-533. 10.1001/archinte.1980.00330160091033, 7362385.
45. Imai K, Toyo'oka T, Watanabe Y. A novel fluorogenic reagent for thiols: ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate. Anal Biochem 1983, 128:471-473. 10.1016/0003-2697(83)90404-9, 6846823.
46. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254. 10.1016/0003-2697(76)90527-3, 942051.
47. Compton SJ, Jones CG. Mechanism of dye response and interference in the Bradford protein assay. Anal Biochem 1985, 151:369-374. 10.1016/0003-2697(85)90190-3, 4096375.
48. Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004, 109:1186-1193. 10.1161/01.CIR.0000118499.69469.51, 14981006.
49. Tepel M, van der GM, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000, 343:180-184. 10.1056/NEJM200007203430304, 10900277.
50. Gonzales DA, Norsworthy KJ, Kern SJ, Banks S, Sieving PC, Star RA, et al. A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: unsupervised clustering to resolve heterogeneity. BMC Med 2007, 5:32. 10.1186/1741-7015-5-32, 2200657, 18001477.
51. Kelly AM, Dwamena B, Cronin P, Bernstein SJ, Carlos RC. Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. Ann Intern Med 2008, 148:284-294.